Cardiac rhythm management devices (part I)

Anesthesiology

Volumn 95, Issue 5, 2001, Pages 1265-1280

  Atlee, John L ^a,e   Bernstein, Alan D ^b,c,d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c Department of Surgery ^*

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVERSION; CHILD; DEFIBRILLATION; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTATION; MEDICAL INSTRUMENTATION; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0034755177     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200111000-00034     Document Type: Review

References (152)

1. The use of an intracardiac pacemaker in the correction of total heart block
2. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings
3. Cardiac pacemakers and antiarrhythmic devices
4. The implantable cardioverter defibrillator
5. Unipolar sensing in contemporary pacemakers: Using myopotential testing to define optimal sensitivity settings
6. Engineering and clinical aspects of pacing leads
7. Improved efficacy of mode switching during atrial fibrillation using automatic atrial sensitivity adjustment
8. Effect of varying atrial sensitivity, AV interval, and detection algorithm on automatic mode switching
9. Reliability of a new algorithm for automatic mode switching from DDDR to DDIR pacing mode in sinus node disease patients with chronotropic incompetence and recurrent paroxysmal atrial fibrillation
10. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the ACC/AHA Task Force on Practice Guidelines (Committee on Pacemaker Implantation)
11. Implantable atrial defibrillator and detection of atrial flutter
12. Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: Observations on treated and nontreated episodes
13. Implantable atrial defibrillator with a single-pass dual-electrode lead
14. Atrial fibrillation detection and R-wave synchronization by Metrix implantable atrial defibrillator: Implications for long-term efficacy and safety
15. Atrioverter: An implantable device for the treatment of atrial fibrillation
16. Temporary cardiac pacing
17. Clinical competence in insertion of a temporary transvenous ventricular pacemaker: A statement for physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology
18. Diagnosis and treatment of arrhythmias during and following open heart surgery
19. Transesophageal electrocardiography and cardiac pacing: State of the art
20. Noninvasive cardiac stimulation revisited
21. Cardiac pacemakers
22. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
23. Cardiac pacing and electroversion
24. Pacing for acute and chronic atrioventricular conduction system disease
25. The natural history of primary first-degree atrioventricular heart block
26. Indications for permanent cardiac pacing in first-degree AV block: Class I, II, or III?
27. Pseudo-pacemaker syndrome following inadvertent fast pathway ablation for atrioventricular nodal reentrant tachycardia
28. Basic physiology of cardiac pacing and the pacemaker syndrome
29. Experience with implantable pacemakers using myocardial electrodes in the management of heart block
30. Prognosis of patients with complete heart block or arrhythmic syncope who were not treated with artificial pacemakers: A longterm follow-up study of 101 patients
31. Nonsurgical acquired heart block
32. Surgical treatment of complete heart block
33. The clinical significance of bundle branch block complicating acute myocardial infarction, 2: Indications for temporary and permanent pacemaker insertion
34. Complete heart block: A clinical, hemodynamic and pharmacological study in patients with and without an artificial pacemaker
35. Natural history of combined right bundle branch block and left anterior hemiblock (bilateral bundle branch block)
36. Syncope in patients with chronic bifascicular block: Significance, causative mechanisms, and clinical implications
37. Association of right bundle-branch block with left superior or inferior intraventricular block: Its relation to complete heart block and Adams-Stokes syndrome
38. Diagnostic value of programmed ventricular stimulation in patients with bifascicular block: A prospective study of patients with and without syncope
39. Clinical implications of electrophysiology study findings in patients with chronic bifascicular block and syncope
40. The risk of advanced heart block in surgical patients with right bundle-branch block and left axis deviation
41. Relationship of right bundle branch block and marked left-axis deviation to complete heart block during general anesthesia
42. Natural history of "high-risk" bundle-branch block: Final report of a prospective study
43. The incidence and mortality of intraventricular conduction defects in acute myocardial infarction
44. Intraventricular conduction disturbances in acute myocardial infarction: Short- and long-term prognosis
45. Long-term prognosis after acute anterior infarction with atrioventricular block
46. Permanent pacing in patients with transient trifascicular block during acute myocardial infarction
47. A simplified method to predict occurrence of complete heart block during acute myocardial infarction
48. Cardiac pacing
49. Benefit of single setting rate responsive ventricular pacing compared with fixed rate demand pacing in elderly patients
50. Chronic sinus node disease: Natural course and indications for pacing
51. Implantable cardioverter defibrillators
52. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome
53. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole
54. Tilt table testing for assessing syncope. American College of Cardiology
55. The North American Vasovagal Pacemaker Study (VPS): A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope
56. Natural history of congenital complete atrioventricular block
57. Congenital complete heart block in patients without anatomic cardiac defects
58. Chronic postsurgical complete heart block with particular reference to prognosis, management, and a new P-wave pacemaaker
59. Atrial arrhythmiaas during chronic follow-up of surgery for complex congenital heart disease
60. Atrial antitachycardia pacing in children and young adults
61. Bradycardia-mediated tachyarrhythmias in congenital heart disease and responses to chronic pacing at physiologic rates
62. Pacemakers in children: An update
63. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease
64. Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome
65. Clinical management of patients with the long QT syndrome: Drugs, devices, and gene-specific therapy
66. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy
67. Impact of dualchamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy
68. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy
69. Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover study
70. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy: Data from 1 year of follow-up. PIC Study Group. Pacing in Cardiomyopathy
71. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Pacing in Cardiomyopathy
72. Assessment of permanent dual-chamber pacing as a treatment for drugrefractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind, crossover study (M-PATHY)
73. Dual-chamber pacing for cardiomyopathies: A 1996 clinical perspective
74. Improvement of cardiac function in patients with severe congestive heart failure and coronary artery disease by dual chamber pacing with shortened AV delay
75. Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy
76. Results of atrioventricular synchronous pacing with optimized delay in patients with severe congestive heart failure
77. Mechanism of hemodynamic improvement by dual-chamber pacing for severe left ventricular dysfunction: An acute Doppler and catheterization hemodynamic study
78. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure
79. Benign prognosis of early sinus node dysfunction after orthotopic cardiac transplantation
80. Decrease in pacemaker incidence after orthotopic heart transplantation
81. Management of atrial flutter after the Fontan procedure
82. NASPE/ACC/AHA/ESC medical/scientific statement special report: Clinical investigation of antiarrhythmic devices: A statement for healthcare professionals from a Joint Task Force of the North American Society of Pacing and Electrophysiology
83. DDD pacing: An effective treatment modality for recurrent atrial arrhythmias
84. Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. DAPPAF Phase 1 Investigators
85. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing
86. Pacing therapy for atrial fibrillation
87. Initial clinical experience with ambulatory use of an implantable atrial defibrillator for conversion of atrial fibrillation
88. Clinical experience with implantable atrial and combined atrioventricular defibrillators
89. The impact of implantable cardioverter defibrillator therapy on health care systems
90. Results of the international study of the implantable pacemaker cardioverter-defibrillator: A comparison of epicardial and endocardial lead systems
91. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator
92. Do patients with an implantable defibrillator live longer?
93. Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest
94. Symptoms and electrocardiographically documented rhythm preceding spontaneous shocks in patients with implantable cardioverter-defibrillator
95. Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy
96. Influence of left ventricular function on survival and mode of death after implantable defibrillator therapy (Cleveland Clinic Foundation and Montefiore Medical Center experience)
97. Survival of implantable cardioverter-defibrillator recipients: Role of left ventricular function and its relationship to device use
98. The Antiarrhythmic versus Implantable Defibrillators (AVID) Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
99. Investigators: Cardiac arrest in Seattle: Conventional versus amiodarone drug evaluation (the CASCADE study)
100. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators
101. A randomized trial of propranolol in patients with acute myocardial infarction, I: Mortality results
102. Beta blockade during and after myocardial infarction: An overview of the randomized trials
103. The role of implantable cardioverter defibrillators in dilated cardiomyopathy
104. Argon laser ablation of malignant ventricular tachycardia associated with coronary artery disease
105. Termination of ventricular tachycardia with epicardial laser photocoagulation: A clinical comparison with patients undergoing successful endocardial photocoagulation alone
106. Bundle branch reentrant ventricular tachycardia: Cumulative experience in 48 patients
107. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease
108. Results of electrical fulguration in arrhythmogenic right ventricular disease
109. Use of implantable cardioverter-defibrillators in the congenital long QT syndrome
110. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
111. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome
112. Right bundle-branch block and ST-segment elevation in leads VI through V3: A marker for sudden death in patients without demonstrable structural heart disease
113. The Brugada syndrome: Clinical, electrophysiologic and genetic aspects
114. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy
115. Arrhythmogenic right ventricular dysplasia: Clinical results with implantable cardioverter-defibrillators
116. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients
117. Expanding indications for permanent pacemakers
118. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Multicenter Automatic Defibrillator Implantation Trial
119. Mechanisms of death in the CABG Patch trial: A randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary, artery bypass graft surgery
120. Early benefit of implantable cardioverter defibrillator therapy in patients waiting for cardiac transplantation
121. The implantable cardioverter defibrillator as a "bridge to transplant": A viable clinical strategy?
122. An overview of sensors: Ideal characteristics, sensor combination, and automaticity
123. Rate-adaptive pacing based on impedance-derived minute ventilation
124. Evoked QT interval-based and intracardiac impedance-based pacemakers
125. Dependence of atrial sensing function on posture in a single-lead atrial triggered ventricular (VDD) pacemaker
126. Extensive variation in the signal amplitude of the atrial floating VDD pacing electrode
127. Dual chamber pacing with a single-lead DDD pacing system
128. Results from the use of a preshaped lead for single-pass VDD/DDD stimulation
129. Timing cycles and operational characteristics of pacemakers
130. Bipolar pacemaker leads: New materials, new technology
131. Pacemaker leads: Performance and progress
132. The proarrhythmic potential of implantable cardioverter-defibrillators
133. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: A prospective study including 200 patients
134. Ventricular arrhythmias detected after transvenous defibrillator implantation in patients with a clinical history of only ventricular fibrillation: Implications for use of implantable defibrillator
135. The NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices
136. Pacemaker and ICD pulse generator circuitry
137. Sensing and arrhythmia detection by implantable devices
138. Prospective comparison of biphasic and monophasic shocks for implantable cardioverter-defibrillators using endocardial leads
139. Clinical efficacy of shock waveforms and lead configurations for defibrillation
140. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease
141. Limitations and late complications of third-generation automatic cardioverter-defibrillators
142. Automatic arrhythmia identification using analysis of the atrioventricular association. Application to a new generation of implantable defibrillators
143. The importance of antitachycardia pacing for patients presenting with ventricular tachycardia
144. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverterdefibrillator implanted with or without thoracotomy: An international multicenter study
145. Conversion rates of induced versus spontaneous ventricular tachycardia by a third generation cardioverter defibrillator
146. The antitachycardia pacing ICD: Impact on patient selection and outcome
147. A prospective randomized repeat-crossover comparison of antitachycardia pacing with low-energy cardioversion
148. The value of DDD pacing in patients with an implantable cardioverter defibrillator
149. The potential usage of dual chamber pacing in patients with implantable cardioverter defibrillators
150. Indications for implantation of a dual-chamber pacemaker combined with an implantable cardioverter-defibrillator